PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
CMB International Global Markets  Equity Research  Company Update
WuXi AppTec (603259 CH)
Strong recovery post COVID-19 disruption
3Q22 earnings in line WuXi AppTec reported 3Q22 revenue of RMB1064bn
RMB238bn up 143% YoY (106%65% YoY for 1Q2Q22) and attributable
1Q2Q22) The Company has experienced a strong recovery from COVID-19
disruption in 2Q22 Earnings are in line with our forecasts with 3Q22 revenue 
2022 full-year estimates Revenue growth in 3Q22 accelerated by 23 ppts to
80% YoY and adjusted Non-IFRS GPM improved by 23 ppts YoY to 386% under
constant currency exchange rates Supported by its solid financial position
WuXi AppTec has decided to terminate its H share placement plan which we
think will boost market sentiment on the stock In addition  management revised
revenue growth guidance to 70-72% YoY from 68-72% YoY for 2022E and
reiterated its revenue CAGR target of over 34% in 2021-24E
 WuXi Chemistry continued to record strong growth from both non-
COVID and COVID CDMO projects WuXi Chemistry revenue jumped by
115% YoY in 3Q22 mainly driven by the 192% YoY revenue growth of
chemical CDMO services Based on our estimates the Company booked
(RMB15bnRMB27bn in 1Q2Q22) accounting for 34% of WuXi
revenue of WuXi Chemistry segment still delivered a solid growth of 41% YoY
in 3Q22 (52%23% YoY in 1Q2Q22) indicating an increasing demand from
non-COVID-19 projects as well Its worth mentioning that CDMO revenue
from oligo  peptide projects increased by more than 4-fold to RMB11bn in
9M22 contributing 13% of chemical CDMO revenue (excluding the
 WuXi Testing and WuXi Biology rebounded from the negative impacts
of COVID-19 pandemic in 2Q22 Revenue of WuXi Testing grew by 28%
YoY in 3Q22 (32%17% YoY for 1Q2Q22) while revenue of WuXi Biology
increased by 37% YoY in 3Q22 (26%12% YoY for 1Q2Q22) WuXi AppTec
assessment medical device testing SMO and drug discovery services (ie
DNA Encoded Compound Library) The Company has built the largest drug
discovery team in the world functioning as a critical project source for its
downstream services such as CDMO and clinical CRO
 Consistent globalization efforts In Aug 2022 WuXi AppTec initiated the
construction of its large-scale drug product manufacturing facilities in
Delaware the US The Company also announced to invest US14bn in next
10 years to build full-suite RD and manufacturing sites in Singapore We
believe its fast-growing global network will enable the Company to better
meet the growing and diversified client demand
 Maintain BUY We revise our TP from HK18517 to HK14220 based on
a 10-year DCF model (WACC 1094% terminal growth rate 30%)
(Previous TP
RMB18517)
UpDownside
Jill WU CFA
Benchen HUANG CFA
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source FactSet
Shareholding Structure
Ge Li and concerted parties
Source Company
Source FactSet
12-mth Price Performance
Source FactSet
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Non-IFRS net profit (RMB mn)
Non-IFRS EPS (RMB)
Consensus EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 Earnings revision
Non-IFRS net profit
Non-IFRS EPS (RMB)
Source Company data CMBIGM estimates
Figure 2 CMBIGM estimates vs consensus
Non-IFRS net profit
Non-IFRS EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
Figure 3 Valuation on risk-adjusted DCF valuation
DCF Valuation (in Rmb mn)
EBIT(1-tax rate)
- Change in working capital
Target Debt to Asset ratio
Effective Corporate Tax Rate
Terminal value (RMB mn)
Total PV (RMB mn)
Net debt (RMB mn)
Equity value (RMB mn)
 of shares (mn)
Price per share (RMB per share)
Source CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
RD expense
Gainloss on financial assets at FVTPL
Investment gainloss
Pre-tax profit
YE 31 Dec (RMB mn)
Cash  equivalents
Financial assets at FVTPL
Non-current assets
Investment in JVs  assos
Financial assets at FVTPL
Other non-current assets
Short-term borrowings
Other current liabilities
Non-current liabilities
Long-term borrowings
Obligations under finance leases
Other non-current liabilities
Total shareholders equity
Total equity and liabilities
YE 31 Dec (RMB mn)
Profit before taxation
Depreciation  amortization
Change in working capital
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Net cash from operations
Acquisition of subsidiaries investments
Net proceeds from disposal of short-term
Net cash from investing
Proceeds from share issues
Net cash from financing
Cash at the beginning of the year
Cash at the end of the year
Adj net profit
Adj net profit margin
Return on equity (ROE)
GEARINGLIQUIDITYACTIVITIES
Net debt to equity (x)
Current ratio (x)
Receivable turnover days
Inventory turnover days
Payable turnover days
PE (diluted)
Div yield (%)
Note The calculation of net cash includes financial assets  Source Company data CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities or is
this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer and (2) no part of his or her co
directly or indirectly related to the specific views expressed by that analyst in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities and
dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report (2) will deal in or trade in t
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM does not provi
advice This report has been prepared without regard to the individual investment objectives financial position or special requirements  Past performance has no indication of
events may differ materially from that which is contained in the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate
consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s)
report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction  Neither CMBIGM nor an
agents consultants directors officers or employees shall be liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the info
Anyone making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable CMBIGM has e
change without notice CMBIGM may issue other publications having information and or conclusions different from this report  These publications reflect different assumption
conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof This report is for the use of intended recipien
be reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from
are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations etc) of the Order and may not be provided to any other person w
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports and the indepen
research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Aut
subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the
intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 as amended
other person in the United States Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distrib
other person Any US recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only throug
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined in the Financi
Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its respective foreign entities affiliates or other foreign research
under Regulation 32C of the Financial Advisers Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an I
the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law S
CMBISG at 65 6350 4400 for matters arising from or in connection with the report